Mitsubishi Gas Chemical Company of Tokyo entered an Asian CRO biologics partnership with US-based Catalent Pharma. Using its GPEx® technology, Catalent will engineer cell lines for the partnership’s clients, and MGC Pharma will provide Phase III and commercial manufacturing. In addition, MGC will use the GPEx technology to offer biosimilar cell lines to clients.
Help employers find you! Check out all the jobs and post your resume.
